Vifor Pharma demonstrated strong momentum in the first half of 2016. Total net sales increased to CHF 550.6 million, up 42.4% from the previous year. Adjusted for currency effects, the increase was 40.8%. The distribution agreement with Roche for Mircera® reached at the end of May 2015 contributed substantial sales of CHF 153.2 million (+242.9%). Income from licensing fees for CellCept totalled CHF 44.3 million compared to CHF 44.5 million in the first half of 2015. Earnings before interest and taxes (EBIT) rose by 28.0% to CHF 185.2 million, while return on sales (ROS) amounted to 33.6%.